<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03744910</url>
  </required_header>
  <id_info>
    <org_study_id>CSL300_3001</org_study_id>
    <secondary_id>2018-003682-34</secondary_id>
    <secondary_id>VKTX01</secondary_id>
    <nct_id>NCT03744910</nct_id>
  </id_info>
  <brief_title>Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients</brief_title>
  <acronym>IMAGINE</acronym>
  <official_title>A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigates the efficacy and safety of clazakizumab [an anti-interleukin (IL)-6&#xD;
      monoclonal antibody (mAb)] for the treatment of CABMR in recipients of a kidney transplant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2019</start_date>
  <completion_date type="Anticipated">November 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to all-cause composite allograft loss</measure>
    <time_frame>Up to 5.5 years</time_frame>
    <description>Defined as return to dialysis, allograft nephrectomy, re-transplantation, eGFR &lt; 15 mL/min/1.73 m2 or death from any cause [including death with functioning allograft]). An eGFR &lt; 15 mL/min/1.73 m2 must be confirmed by a repeat measurement taken between 14 to 30 days later. Temporary return to dialysis due to AKI and temporary eGFR decline to &lt; 15 mL/min/1.73 m2 due to AKI are both excluded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and time to death-censored allograft loss</measure>
    <time_frame>Up to 5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean estimated glomerular filtration rate (eGFR) from Baseline to End of Treatment (EOT)</measure>
    <time_frame>Baseline and Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spot urine albumin creatinine ratio (UACR) from Baseline to EOT</measure>
    <time_frame>Baseline and Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in (Donor-specific antibodies) DSA titers and Mean fluorescence intensity (MFI) scores from Baseline to EOT</measure>
    <time_frame>Baseline and Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejection episodes of T cell-mediated rejection(TCMR) and Antibody-mediated rejection (ABMR) from Baseline to EOT</measure>
    <time_frame>Baseline and Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Banff lesion grading score (2015 criteria) of pre-treatment to post-treatment (Week 52) kidney biopsies</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient survival</measure>
    <time_frame>Up to 5.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax, Cmax ss) of CSL300</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough serum concentrations (Ctrough, Ctrough ss) of CSL300</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC0-tau) at steady state of CSL300</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum serum concentration (Tmax, Tmax ss) of CSL300</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Antibody-mediated Rejection</condition>
  <arm_group>
    <arm_group_label>Clazakizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6 that is administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiologic saline solution that is administered subcutaneously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clazakizumab</intervention_name>
    <description>Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6</description>
    <arm_group_label>Clazakizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physiologic saline solution</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria:&#xD;
&#xD;
               1. Age 18-70 years.&#xD;
&#xD;
               2. Living donor/deceased donor kidney transplant recipients ≥6 months from time of&#xD;
                  transplant.&#xD;
&#xD;
               3. Diagnosis of CABMR determined by kidney biopsy and the presence of HLA DSA using&#xD;
                  single-antigen bead-based assays.&#xD;
&#xD;
                  NOTE: If conducted within 6 months (+3 weeks) of the start of the screening&#xD;
                  period, the biopsy and DSA analysis do not need to be repeated at screening. To&#xD;
                  be considered for determination of study eligibility, the biopsy and DSA analysis&#xD;
                  must be performed at least 2 months ± 2 weeks after the end of any prior&#xD;
                  treatment for ABMR (including CABMR) or TCMR, in order to show continuing CABMR&#xD;
                  and presence of HLA DSA. In addition, treatments for ABMR or TCMR are not allowed&#xD;
                  within 3 months of the start of screening.&#xD;
&#xD;
                  The following histopathologic and serologic diagnostic criteria (based on Banff&#xD;
                  2015 criteria [Loupy et al, 2017]) must be met for inclusion:&#xD;
&#xD;
                    -  Morphologic evidence of chronic tissue injury, as demonstrated by TG (cg&gt;0).&#xD;
                       Biopsies without evidence of chronic tissue injury on light microscopy, but&#xD;
                       with glomerular basement membrane double contours on electron microscopy&#xD;
                       (cg1a) are eligible.&#xD;
&#xD;
                    -  Evidence of current/recent antibody interaction with vascular endothelium,&#xD;
                       including 1 or more of the following.&#xD;
&#xD;
                    -  Linear C4d staining in peritubular capillaries or medullary vasa recta (C4d2&#xD;
                       or C4d3 by immunofluorescence on frozen sections, or C4d &gt; 0 by&#xD;
                       immunohistochemistry on paraffin sections).&#xD;
&#xD;
                    -  At least moderate microvascular inflammation ([g + ptc] ≥ 2) in the absence&#xD;
                       of recurrent or de novo glomerulonephritis, although in the presence of&#xD;
                       acute TCMR, borderline infiltrate, or infection, ptc ≥ 2 alone is not&#xD;
                       sufficient and g must be ≥ 1.&#xD;
&#xD;
                  NOTE: The local pathologist's diagnosis must be reviewed by a central pathologist&#xD;
                  to confirm eligibility for entry into the study. Biopsies with other&#xD;
                  histopathologic changes (eg, BKV nephropathy or recurrent glomerulonephritis) may&#xD;
                  be eligible if concurrent CABMR changes (as detailed above) are present and&#xD;
                  determined to be the predominant cause of renal dysfunction.&#xD;
&#xD;
               4. Serologic evidence of circulating DSA to HLA. NOTE: The local laboratory DSA&#xD;
                  results must be reviewed and confirmed by the central HLA reviewer during the&#xD;
                  screening period.&#xD;
&#xD;
          -  Exclusion criteria:&#xD;
&#xD;
               1. Multi-organ transplant recipient (except for simultaneous kidney-pancreas or&#xD;
                  previous multiple kidney transplants) or cell transplant (islet, bone marrow,&#xD;
                  stem cell) recipient.&#xD;
&#xD;
               2. Treatment for ABMR (including CABMR) or TCMR within 3 months of the start of&#xD;
                  screening.&#xD;
&#xD;
               3. Received T cell depleting agents (e.g., alemtuzumab, anti-thymocyte globulin)&#xD;
                  within 3 months of the start of screening.&#xD;
&#xD;
               4. Pregnant, breastfeeding, or unwillingness to practice adequate contraception.&#xD;
&#xD;
               5. History of active tuberculosis (TB).&#xD;
&#xD;
               6. History of human immunodeficiency virus (HIV) infection or positive for HIV.&#xD;
&#xD;
               7. Seropositive for hepatitis B surface antigen (HBsAg)&#xD;
&#xD;
               8. Hepatitis C virus (HCV) RNA positive.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Registration Coordinator</last_name>
    <phone>610-878-4000</phone>
    <email>clinicaltrials@cslbehring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>480-342-2536</phone>
    </contact>
    <investigator>
      <last_name>Hasan Khamash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Gripp</last_name>
      <phone>858-637-4600</phone>
    </contact>
    <investigator>
      <last_name>Arman Faravardeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NU Comprehensive Transplant Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-964-0234</phone>
    </contact>
    <investigator>
      <last_name>John Friedewald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center/ Maine Medical Center Research Institute</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>207-396-8184</phone>
    </contact>
    <investigator>
      <last_name>John Vella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-328-0303</phone>
    </contact>
    <investigator>
      <last_name>Matthew Weir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>313-916-4596</phone>
    </contact>
    <investigator>
      <last_name>Milagros Samaniego-Picota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>507-538-9617</phone>
    </contact>
    <investigator>
      <last_name>Carrie Schinstock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Assistant</last_name>
      <phone>402-552-2285</phone>
    </contact>
    <investigator>
      <last_name>Eric Langewisch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>347-671-8217</phone>
    </contact>
    <investigator>
      <last_name>Enver Akalin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-263-3620</phone>
    </contact>
    <investigator>
      <last_name>Infana Soomro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>212-305-6842</phone>
    </contact>
    <investigator>
      <last_name>David Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>336-716-9353</phone>
    </contact>
    <investigator>
      <last_name>Colleen Jay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>513-558-9965</phone>
    </contact>
    <investigator>
      <last_name>Ervin Woodle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Pennsylvania Transplant Foundation</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>717-251-8765</phone>
    </contact>
    <investigator>
      <last_name>Manpreet Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-792-7558</phone>
    </contact>
    <investigator>
      <last_name>Vinaya Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Nephrology Clinical Trials</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>615-936-1179</phone>
    </contact>
    <investigator>
      <last_name>Harold Helderman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Disease Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-366-6133</phone>
    </contact>
    <investigator>
      <last_name>Bernard Fischbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VCU Health</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-382-2243</phone>
    </contact>
    <investigator>
      <last_name>Guarav Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-598-1562</phone>
    </contact>
    <investigator>
      <last_name>Nicolae Leca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Medical Research Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>509-474-4302</phone>
    </contact>
    <investigator>
      <last_name>Samer Bani Hani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health (UWSMPH)</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Coordinator</last_name>
      <phone>608-265-6544</phone>
    </contact>
    <investigator>
      <last_name>Arjang Djamali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Steven Chadban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WSLHD, Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Coordinator</last_name>
      <phone>61288906848</phone>
    </contact>
    <investigator>
      <last_name>Philip O'Connell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>3176 6325</phone>
    </contact>
    <investigator>
      <last_name>Scott Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>61 8 7074 3077</phone>
    </contact>
    <investigator>
      <last_name>Toby Coates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>03 9594 3521</phone>
    </contact>
    <investigator>
      <last_name>William Mulley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3064</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Coordinator</last_name>
      <phone>61393424744</phone>
    </contact>
    <investigator>
      <last_name>Peter Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital - Gordon &amp; Leslie Diamond Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>604 682 2344</phone>
      <phone_ext>64706</phone_ext>
    </contact>
    <investigator>
      <last_name>Olwyn Johnston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital, Providence Health Care, Univ. Of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>604 682 2344</phone>
    </contact>
    <investigator>
      <last_name>John Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shared Health Inc. operating as the Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <contact_backup>
      <phone>204-787-8662</phone>
    </contact_backup>
    <investigator>
      <last_name>Peter Nickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>902-473-7625</phone>
    </contact>
    <investigator>
      <last_name>Amanda Vinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>519-685-8500 x 34769</phone>
    </contact>
    <investigator>
      <last_name>Anthony Jevnikar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>514-934-1934 ext 36569</phone>
    </contact>
    <investigator>
      <last_name>Marcelo Cantarovich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Paul's Hospital Foundation</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7M 0Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>306 655 5990</phone>
    </contact>
    <investigator>
      <last_name>Ahmed Shoker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IKEM</name>
      <address>
        <city>Prague</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>420261362144</phone>
    </contact>
    <investigator>
      <last_name>Ondrej Viklicky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU GRENOBLE ALPES - Consultation Néphrologie Bureau des ARC (Côté Chartreuse, Rez-de-Chaussée Haut)</name>
      <address>
        <city>Grenoble</city>
        <state>Grenoble Cédex 09</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>04 76 76 72 62</phone>
    </contact>
    <investigator>
      <last_name>Lionel Rostaing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Néphrologie - Pavillon Sainte Venise - CHU de Rouen - Hôpital de Bois Guillaume</name>
      <address>
        <city>Bois-Guillaume</city>
        <zip>76230</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>02 32 88 9152</phone>
    </contact>
    <investigator>
      <last_name>Dominique Bertrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33 4 72 11 62 20</phone>
    </contact>
    <investigator>
      <last_name>Emmanuel Morelon, Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Aubert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33 5 61 32 28 94</phone>
    </contact>
    <investigator>
      <last_name>Nassim Kamar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lead Study Coordinator</last_name>
      <phone>004930 450614183</phone>
    </contact>
    <investigator>
      <last_name>Klemens Budde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem, Klinikai Központ, Auguszta</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>36 30 670 7453</phone>
    </contact>
    <investigator>
      <last_name>Balazs Nemes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>36306599227</phone>
    </contact>
    <investigator>
      <last_name>Gyorgy Lazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nurse</last_name>
      <phone>31243614761</phone>
    </contact>
    <investigator>
      <last_name>Luuk Hilbrands, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC location AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Co-ordinator</last_name>
      <phone>0031-205661168</phone>
    </contact>
    <investigator>
      <last_name>Frederike Bemelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+31-10-703 46 07</phone>
    </contact>
    <investigator>
      <last_name>Michiel Betjes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCUtrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00318875 59768</phone>
    </contact>
    <investigator>
      <last_name>Arjan Van Zuilen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34932483689</phone>
    </contact>
    <investigator>
      <last_name>Marta Crespo Barrio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>93 274 60 00 ext. 4872</phone>
    </contact>
    <investigator>
      <last_name>Daniel Seron Micas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34932275400</phone>
      <phone_ext>4408</phone_ext>
    </contact>
    <investigator>
      <last_name>Fritz Diekmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>8907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>34932607385</phone>
    </contact>
    <investigator>
      <last_name>Jose Maria Cruzado Garrit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>976765624</phone>
    </contact>
    <investigator>
      <last_name>Alex Gutierrez Dalmau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Active</keyword>
  <keyword>Antibody-mediated Rejection (AMR)</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

